Michael King
Stock Analyst at EF Hutton
(0.90)
# 3,998
Out of 5,150 analysts
107
Total ratings
37.17%
Success rate
-10.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $20.51 | +3,069.19% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $2.82 | +290.07% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.39 | +2,202.16% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.42 | +4,723.94% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $12.98 | +1,440.83% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.61 | +1,255.10% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $787.50 | +9.46% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $41.69 | -42.43% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $3.20 | +5,087.50% | 8 | Mar 28, 2023 | |
| XNCR Xencor | Reiterates: Buy | $42 | $12.74 | +229.67% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $327.30 | -7.12% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $13.82 | +739.36% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.69 | +81.02% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $47.43 | -49.40% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $60.55 | -24.03% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $28.19 | +240.55% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.54 | +6,510.36% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $37.02 | -16.26% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $749.56 | -95.20% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $20.51
Upside: +3,069.19%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $2.82
Upside: +290.07%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.39
Upside: +2,202.16%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.42
Upside: +4,723.94%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $12.98
Upside: +1,440.83%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.61
Upside: +1,255.10%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $787.50
Upside: +9.46%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $41.69
Upside: -42.43%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $3.20
Upside: +5,087.50%
Xencor
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $12.74
Upside: +229.67%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $327.30
Upside: -7.12%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $13.82
Upside: +739.36%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $5.69
Upside: +81.02%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $47.43
Upside: -49.40%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $60.55
Upside: -24.03%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $28.19
Upside: +240.55%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.54
Upside: +6,510.36%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $37.02
Upside: -16.26%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $749.56
Upside: -95.20%